Navigation Links
Varian Medical Systems Schedules First Quarter FY2009 News Release and Conference Call
Date:12/10/2008

PALO ALTO, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) announced today that it will report results for first quarter of fiscal year 2009 following the close of regular trading on Thursday, January 29, 2009. The news release will be followed by a teleconference available to all interested parties at 2:00 p.m. PT.

The Varian Medical Systems quarterly results can be accessed on January 29, 2009. The news release and information on the conference call webcast will be available on the company website at: www.varian.com/investor. Details on the conference call and replay follow:

    Teleconference:   Telephone from within the U.S.:
                      -- Dial 1-866-271-0675 and enter access code
                         46529406 prior to the call at
                         2:00 p.m. PT/5:00 p.m. ET.
                         Telephone from outside the U.S.:
                      -- Dial 1-617-213-8892 and enter access code
                         46529406 prior to the call at
                         2:00 p.m. PT/5:00 p.m. ET.
                      *Note: If the number of lines allocated to the
                      call is exhausted, the webcast or replay should be
                      utilized.

    Replay:           The teleconference will be rebroadcast until
                      8:00 p.m. ET, Friday, January 30, 2009 and can be
                      accessed by phone or Web link as follows:
                      -- Telephone from within the U.S.: Dial
                         1-888-286-8010 and enter access code 54317886.
                      -- Telephone from outside the U.S.: Dial
                         1-617-801-6888 and enter access code 54317886.
                      -- Internet: Click on the "Quarterly Conference Call"
                         icon on the company's investor relations website
                         at www.varian.com/investor
                      -- Web conferences will be archived on the company
                         website for a year.

For automatic "e-mail alerts" regarding Varian news and events investors can subscribe on the company website: http://varian.investorroom.com/index.php?s=58.

For additional information contact Anne Rambo at 650-424-5834 or anne.rambo@varian.com.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,800 people who are located at manufacturing sites in North America and Europe and in its 60 sales and support offices around the world. For more information, visit http://www.varian.com/.

    FOR INFORMATION CONTACT:
    Spencer Sias, (650) 424-5782
    Vice President, Corporate Communications
    and Investor Relations
    spencer.sias@varian.com


'/>"/>
SOURCE Varian Medical Systems
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NEW Line of Pushbutton Pill Cases Launched by Variant Products
2. Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto
3. Few Ontario women with invasive ovarian cancer referred for genetic testing of breast cancer genes
4. International study supports new standard of treatment for women with advanced ovarian cancer
5. Study unmasks how ovarian tumors evade immune system
6. Varian Medical Systems to Exhibit the Latest X-Ray Image Detectors, X-Ray Tubes, and Cancer Treatment Technologies at RSNA This Year
7. Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer
8. New platinum-phosphate compounds kill ovarian cancer cells
9. Protein compels ovarian cancer cells to cannibalize themselves
10. Top Indian Cancer Hospital to Introduce Advanced Radiosurgery Treatments With Novalis Tx from Varian Medical Systems and BrainLAB
11. Varian Medical Systems Schedules Fiscal Year End Review in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... An April 24th article on Yahoo! ... 180 pounds with the help of a weight loss surgery. The woman, declaring “I will ... that have been left following her dramatic weight loss. Dr. Feiz & Associates notes that, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading provider ... Online(TM), which enables sleep physicians to create and edit their interpretation reports. This ... provides a familiar interface that does not require additional training to use. It ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic ... has joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board ... Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... ... cardiac or hERG liability could substantially improve drug safety and minimize the cost ... provided for validating ion channel inhibition using cell lines and for cardiac toxicity ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: